Skip to main content
Premium Trial:

Request an Annual Quote

Meridian's C. Difficile MDx Assay Receives FDA Clearance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared Meridian Bioscience's illumigene C. difficile molecular amplification assay, the company announced today.

In a statement, Cincinnati, Ohio-based Meridian said that the assay detects the presence of the toxin-producing region from the Clostridium difficile DNA and provides "highly accurate" results in less than an hour. The system allows for diagnosis of the disease with "high levels of sensitivity," and its "simple workflow requires minimal hands-on time per sample," the company said.

The illumigene C. difficile system was recently launched in Europe. Meridian submitted a 510(k) application with FDA for the test in March.

C. difficile is a bacterium that causes diarrhea and in extreme cases, life-threatening inflammation of the colon.

The test is the first molecular diagnostic product for Meridian, which makes diagnostic tests for gastrointestinal and upper respiratory infections, serology, parasitology, and fungal diseases. It is based on Meridian's loop amplification technology, which is isothermal and requires no costly capital equipment, according to the firm.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.